AN INVESTIGATION OF IMMUNOGENICITY OF CHITOSAN-BASED BOTULINUM NEUROTOXIN E BINDING DOMAIN RECOMBINANT CANDIDATE VACCINE VIA MUCOSAL ROUTE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BAGHERIPOUR MOHAMMAD JAVAD; EBRAHIMI FIROUZ; HAJIZADEH ABBAS; NAZARIAN SHAHRAM; ZARGAN JAMIL; RASHIDIANI JAMAL

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: QOM UNIVERSITY OF MEDICAL SCIENCES JOURNAL Year:2016 | Volume:10 | Issue:10 Page(s): 7-16

Download Full-Text

Persian Verion

View:

674

Download:

Cites:

Information Journal Paper

Title

AN INVESTIGATION OF IMMUNOGENICITY OF CHITOSAN-BASED BOTULINUM NEUROTOXIN E BINDING DOMAIN RECOMBINANT CANDIDATE VACCINE VIA MUCOSAL ROUTE

Author(s)

Keywords

CHITOSANQ1

NANOPARTICLESQ1

VACCINESQ1

IONIC GELATIONQ1

BOTULISMQ1

Abstract

Background and Objectives: BOTULISM syndrome is caused by serotypes A-G of neurotoxins of Clostridium genus. Neurotoxin binding domain is an appropriate vaccine candidate due to its immunogenic activity. In this study, the immunogenicity of CHITOSANbased botulinum neurotoxin E binding domain recombinant candidate vaccine was investigated via mucosal route of administration.Methods: In this experimental study, CHITOSAN NANOPARTICLES containing rBoNT/E protein were synthesized by IONIC GELATION method and were administered orally and intranasally to mice. After each administration, IgG antibody titer was measured by ELISA method. Finally, all groups were challenged with active botulinum neurotoxin type E. Data were analyzed using Duncan and repeated ANOVA tests. The significance level was considered as p<0.05.Results: After each administration, IgG antibody titre was increased in all the test groups (except the control group). According to the results of challenge with active botulinum neurotoxin type E, the mice immunized orally and intranasally by NANOPARTICLES containing the antigen and also the mice that only received the antigen orally, could tolerate 500 folds of LD50. The group immunized intranasally with only antigen tolerated 2000 folds of LD50.Conclusion: The results of this research showed that use of CHITOSAN NANOPARTICLES has no significant increase in the immunogenicity of recombinant botulinum neurotoxin antigen in oral and intranasal routes (p>0.05), even intranasal route reduced the immunogenicity.

Cites

No record.

References

No record.

Cite

APA: Copy

BAGHERIPOUR, MOHAMMAD JAVAD, EBRAHIMI, FIROUZ, HAJIZADEH, ABBAS, NAZARIAN, SHAHRAM, ZARGAN, JAMIL, & RASHIDIANI, JAMAL. (2016). AN INVESTIGATION OF IMMUNOGENICITY OF CHITOSAN-BASED BOTULINUM NEUROTOXIN E BINDING DOMAIN RECOMBINANT CANDIDATE VACCINE VIA MUCOSAL ROUTE. QOM UNIVERSITY OF MEDICAL SCIENCES JOURNAL, 10(10), 7-16. SID. https://sid.ir/paper/132357/en

Vancouver: Copy

BAGHERIPOUR MOHAMMAD JAVAD, EBRAHIMI FIROUZ, HAJIZADEH ABBAS, NAZARIAN SHAHRAM, ZARGAN JAMIL, RASHIDIANI JAMAL. AN INVESTIGATION OF IMMUNOGENICITY OF CHITOSAN-BASED BOTULINUM NEUROTOXIN E BINDING DOMAIN RECOMBINANT CANDIDATE VACCINE VIA MUCOSAL ROUTE. QOM UNIVERSITY OF MEDICAL SCIENCES JOURNAL[Internet]. 2016;10(10):7-16. Available from: https://sid.ir/paper/132357/en

IEEE: Copy

MOHAMMAD JAVAD BAGHERIPOUR, FIROUZ EBRAHIMI, ABBAS HAJIZADEH, SHAHRAM NAZARIAN, JAMIL ZARGAN, and JAMAL RASHIDIANI, “AN INVESTIGATION OF IMMUNOGENICITY OF CHITOSAN-BASED BOTULINUM NEUROTOXIN E BINDING DOMAIN RECOMBINANT CANDIDATE VACCINE VIA MUCOSAL ROUTE,” QOM UNIVERSITY OF MEDICAL SCIENCES JOURNAL, vol. 10, no. 10, pp. 7–16, 2016, [Online]. Available: https://sid.ir/paper/132357/en

Related Journal Papers